Last reviewed · How we verify

Continuous intravenous analgesia

University Hospital of Split · FDA-approved active Small molecule Quality 5/100

Continuous intravenous analgesia, marketed by the University Hospital of Split, holds a niche position in the pain management segment. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk lies in the lack of detailed revenue data and key trial results, which may limit investor confidence and competitive positioning.

At a glance

Generic nameContinuous intravenous analgesia
Also known asContinuous tramadol infusion, Continuous tramadol analgesia
SponsorUniversity Hospital of Split
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: